Filing Flows › Theravance Biopharma (TBPH) › Q2 2026
Theravance Biopharma (TBPH) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 11, 2026
Theravance Biopharma (TBPH) reported revenue of $20.7M for the second quarter 2026 (Q2 2026), -21% from a year earlier and +17% from the quarter before. Operating margin was -39.9%, net loss $5.9M (28.5% of revenue).
Theravance Biopharma, Q2 2026: revenue $20.7M (-21% year over year), operating margin -39.9%, net loss $5.9M, operating cash flow −$7.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.7M | +17% | -21% |
| Operating profit | −$8.3M | — | — |
| Net earnings | −$5.9M | — | -111% |
| Operating cash flow | −$7.0M | -110% | -103% |
What changed
Revenue was $20.7M in Q2 2026, down 21% year over year and up 17% from the previous quarter.
Operating costs exceeded revenue by $8.3M, an operating margin of -39.9%. Total costs grew 0% against a revenue fall of 21%. The quarter ended with a net loss of $5.9M, wider than the previous quarter's $4.9M loss. Non-operating items added $3.5M, -73% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$7.0M. Non-cash charges added back $6.0M of share-based compensation. Working capital and other items used $7.1M.
Questions
What was Theravance Biopharma's revenue in the second quarter 2026?
Theravance Biopharma (TBPH) reported revenue of $20.7M for the second quarter 2026 (Q2 2026), -21% from a year earlier and +17% from the quarter before.
Was Theravance Biopharma profitable in the second quarter 2026?
Operating loss was $8.3M (-39.9% of revenue) and net loss $5.9M.